Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas G Bader

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 14, 2005
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenicSohye Kang, Andreas G Bader, Peter K Vogt
Virology|December 21, 2005
Phosphoinositide 3-kinase: from viral oncoprotein to drug targetPeter K Vogt, Andreas G Bader, Sohye Kang
Cell Cycle (Georgetown, Tex.)|May 12, 2006
PI 3-kinases: hidden potentials revealedPeter K Vogt, Andreas G Bader, Sohye Kang
Cell Cycle (Georgetown, Tex.)|May 7, 2005
Mutated PI 3-kinases: cancer targets on a silver platterSohye Kang, Andreas G Bader, Li Zhao, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 10, 2013
TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.)Jane Zhao, Paul Lammers, Chris J Torrance, et al.
Nature Reviews. Cancer|December 13, 2005
Oncogenic PI3K deregulates transcription and translationAndreas G Bader, Sohye Kang, Li Zhao, et al.
Virology|July 8, 2008
TOJ3, a v-jun target with intrinsic oncogenic potential, is directly regulated by Jun via a novel AP-1 binding motifAntonios I Karagiannidis, Andreas G Bader, Markus Hartl, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancerJane Zhao, Adriana Guerrero, Kevin Kelnar, et al.
Analytical Chemistry|January 9, 2014
Quantification of therapeutic miRNA mimics in whole blood from nonhuman primatesKevin Kelnar, Heidi J Peltier, Neil Leatherbury, et al.
Expert Opinion on Therapeutic Targets|December 14, 2007
Applying small RNA molecules to the directed treatment of human diseases: realizing the potentialTodd C Pappas, Andreas G Bader, Bernard F Andruss, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|January 14, 2005
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenicSohye Kang, Andreas G Bader, Peter K Vogt
Virology|December 21, 2005
Phosphoinositide 3-kinase: from viral oncoprotein to drug targetPeter K Vogt, Andreas G Bader, Sohye Kang
Cell Cycle (Georgetown, Tex.)|May 12, 2006
PI 3-kinases: hidden potentials revealedPeter K Vogt, Andreas G Bader, Sohye Kang
Cell Cycle (Georgetown, Tex.)|May 7, 2005
Mutated PI 3-kinases: cancer targets on a silver platterSohye Kang, Andreas G Bader, Li Zhao, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 10, 2013
TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.)Jane Zhao, Paul Lammers, Chris J Torrance, et al.
Nature Reviews. Cancer|December 13, 2005
Oncogenic PI3K deregulates transcription and translationAndreas G Bader, Sohye Kang, Li Zhao, et al.
Virology|July 8, 2008
TOJ3, a v-jun target with intrinsic oncogenic potential, is directly regulated by Jun via a novel AP-1 binding motifAntonios I Karagiannidis, Andreas G Bader, Markus Hartl, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancerJane Zhao, Adriana Guerrero, Kevin Kelnar, et al.
Analytical Chemistry|January 9, 2014
Quantification of therapeutic miRNA mimics in whole blood from nonhuman primatesKevin Kelnar, Heidi J Peltier, Neil Leatherbury, et al.
Expert Opinion on Therapeutic Targets|December 14, 2007
Applying small RNA molecules to the directed treatment of human diseases: realizing the potentialTodd C Pappas, Andreas G Bader, Bernard F Andruss, et al.
Pageof 4